Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CRN09682 · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| Dose Escalation | EXPERIMENTAL | Multiple Dose Levels administered Q3W |
| Dose Expansion: Cohort 1 | EXPERIMENTAL | Pancreatic Neuroendocrine Tumor (NET) |
| Dose Expansion: Cohort 2 | EXPERIMENTAL | Non-Pancreatic NET |
| Dose Expansion: Cohort 3 | EXPERIMENTAL | Neuroendocrine Carcinoma (NEC) |
| Dose Expansion: Cohort 4 | EXPERIMENTAL | Other Solid Tumors |
| Name | Type | Description |
|---|---|---|
| CRN09682 | DRUG | Study drug CRN09682 intravenously |
Inclusion Criteria: * Have a histological diagnosis of metastatic or locally advanced inoperable NET, NEC, or other solid tumors that have confirmed radiological progression. * Have one or more measurable disease location per RECIST version 1.1. * Have a tumor that expresses SSR confirmed by SSR im...
CRN09682 is an investigational small molecule developed by Crinetics Pharmaceuticals, Inc. (ticker CRNX) for SST2-positive neuroendocrine neoplasms. It is in Phase 1 clinical development in oncology and is designed to target SST2, a receptor expressed on certain neuroendocrine tumors. It has not been approved by the FDA and remains under clinical study.
CRN09682 is being studied for the treatment of SST2-positive neuroendocrine neoplasms, including neuroendocrine tumors and neuroendocrine neoplasm. It is an investigational therapy in Phase 1 development and is not approved for any indication. The ongoing trial also enrolls participants with other solid tumors that express SST2.
CRN09682 targets SST2, also known as somatostatin receptor 2. SST2 is expressed on SST2-positive neuroendocrine neoplasms, and the trial selects participants based on this biomarker. By binding SST2, the small molecule is designed to act on tumors that express this receptor, which is the basis for its biomarker-selected development in oncology.
CRN09682 is being developed by Crinetics Pharmaceuticals, Inc., which trades under the ticker CRNX. The company is the sponsor of the Phase 1 clinical program evaluating the small molecule in SST2-positive neuroendocrine neoplasms and other solid tumors expressing SST2.
CRN09682 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The Phase 1 program is currently active, with one trial listed as active and not recruiting, and no completed trials reported to date.
CRN09682 is being evaluated in the Phase 1 trial NCT07129252, titled A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors. The trial is active but not recruiting, plans to enroll 150 participants aged 18 years and older, and is running in the United States and Spain.